Regulatory Articles. App Notes, Case Studies. & White Papers

1. FDA's New Flexible CMC Framework For CGT 4/14/2026

   The FDA is rethinking CMC oversight for cell and gene therapies, prioritizing science‑based justification over rigid validation models. Learn how this lifecycle‑focused approach could reduce burden.

2. Industry Innovators: APAC's Sharp Advanced Therapeutics Edge 3/17/2026

   APAC is rapidly advancing its role in the global therapeutics landscape, fueled by faster development models. Learn how this momentum is reshaping expectations for innovation and commercialization.

3. Flow Chemistry For Contemporary Isotope Labeling 1/26/2026

   Gain insight into how late‑stage exchange and flow‑based methods enable efficient access to labeled molecules for pharmaceuticals, mechanistic studies, and analytical applications.

4. Your Biosimilar, Your Journey 10/20/2025

   With many blockbuster drug patents set to expire by 2030, the market is ripe for biosimilar developers to stake their claim. To succeed, they must be strategic and compliant.

5. A Risk-Based Approach To Plasmid DNA And mRNA Process Development 9/23/2025

   Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.

6. Cell And Gene Therapy In Conversation 9/8/2025

   Industry experts share strategies to overcome key barriers in CGT development, from reproducibility to scale-up. Gain practical insights to help teams move faster and more reliably toward commercialization.

7. Navigating The Regulatory Space To Biosimilar Approval 9/1/2025

   The biosimilar patent cliff is reshaping pharma, creating unprecedented opportunities for biotech and CDMOs. Explore expert regulatory support that can help you navigate this shift with confidence.

8. Zero To Final Fill: How HUGEL Implemented Its First Single-Use Lines 8/6/2025

   As regulations tighten, biomanufacturers are adopting single-use tech to boost compliance, reduce labor, and streamline fill-finish operations from the ground up.

9. Risk Assessment Services Align With FDA Guidance For Gene-Edited Human Gene Therapy Products 7/29/2025

   Navigate the FDA's gene therapy guidelines with advanced risk assessment strategies. Optimize gene editing and ensure regulatory alignment for safer, more effective therapies.

10. The Patent Cliff Looms – Design Your Biosimilar Approach Accordingly 3/3/2025

    In your pursuit of developing a high-quality biosimilar, think strategically. Consider what type of biologic your team’s expertise can support and which is needed most in your target market.